Analysts expect that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will post earnings of ($1.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Alder Biopharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.36) and the highest estimate coming in at ($0.99). Alder Biopharmaceuticals reported earnings of ($0.92) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 22.8%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.73) per share for the current financial year, with EPS estimates ranging from ($5.50) to ($4.09). For the next fiscal year, analysts expect that the company will post earnings of ($3.59) per share, with EPS estimates ranging from ($5.46) to ($2.50). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Alder Biopharmaceuticals.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.01.

Several equities analysts have weighed in on the company. ValuEngine upgraded Alder Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. BMO Capital Markets raised their target price on Alder Biopharmaceuticals from $21.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. BidaskClub lowered Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 17th. Piper Jaffray Companies assumed coverage on Alder Biopharmaceuticals in a report on Monday, August 6th. They set an “overweight” rating and a $28.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on Alder Biopharmaceuticals in a report on Tuesday, August 7th. They set a “buy” rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. Alder Biopharmaceuticals has a consensus rating of “Buy” and a consensus target price of $23.33.

ALDR traded down $0.70 during trading on Tuesday, reaching $16.35. 912,078 shares of the stock traded hands, compared to its average volume of 1,239,459. Alder Biopharmaceuticals has a fifty-two week low of $9.55 and a fifty-two week high of $20.87. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.73. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -3.30 and a beta of 2.59.

In other news, insider John A. Latham sold 24,999 shares of Alder Biopharmaceuticals stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $15.48, for a total value of $386,984.52. Following the transaction, the insider now directly owns 268,692 shares in the company, valued at $4,159,352.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey T. L. Smith sold 5,040 shares of Alder Biopharmaceuticals stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $18.00, for a total value of $90,720.00. Following the completion of the transaction, the director now owns 5,871 shares in the company, valued at $105,678. The disclosure for this sale can be found here. Insiders sold 97,238 shares of company stock worth $1,703,022 over the last quarter. 17.40% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of ALDR. Flinton Capital Management LLC bought a new position in shares of Alder Biopharmaceuticals in the first quarter worth about $100,000. SG Americas Securities LLC bought a new position in shares of Alder Biopharmaceuticals in the second quarter worth about $107,000. Neuburgh Advisers LLC bought a new position in shares of Alder Biopharmaceuticals in the first quarter worth about $121,000. Tower Research Capital LLC TRC bought a new position in shares of Alder Biopharmaceuticals in the second quarter worth about $128,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Alder Biopharmaceuticals in the first quarter worth about $142,000.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Featured Article: Technical Analysis

Get a free copy of the Zacks research report on Alder Biopharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.